Developer docs
API playgroundTry for free, no card

Search company profiles

Cardurion Pharmaceuticals

Full company profile

uuid0000ny4

Namestring
Cardurion Pharmaceuticals
Legal namestring
Cardurion Pharmaceuticals, Inc.
Websiteurl
cardurion.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Cardurion Pharmaceuticals is a clinical-stage cardiovascular biotechnology company founded in 2017 by physician-scientist Michael E. Mendelsohn, M.D. (former Senior Vice President and Global Head of Cardiovascular Research at Merck Research Laboratories) and headquartered in Burlington, Massachusetts. The company develops novel therapeutics targeting cardiovascular signaling pathways — specifically phosphodiesterase 9 (PDE9) and calcium/calmodulin-dependent protein kinase II (CaMKII) — both previously considered difficult or "undruggable." Its lead program, CRD-750 (a PDE9 inhibitor), is being evaluated in two global Phase 2 trials: CYCLE-1-REF in heart failure with reduced ejection fraction (HFrEF, ~560 patients) and CYCLE-2-PEF in heart failure with preserved ejection fraction (HFpEF, ~300 patients), with enrollment completed in August 2025. A related molecule, CRD-740, generated statistically significant plasma cGMP increases in the Phase 2a CARDINAL-HF trial in HFrEF patients. The CaMKII inhibitor program is anchored by CRD-4730 in a Phase 2 trial for catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare genetic arrhythmic disease with no approved therapies, and is being explored for broader applications in heart failure and atrial fibrillation.

The company's core technology platforms — PDE9 inhibition (preventing cGMP degradation to enhance natriuretic peptide signaling) and CaMKII inhibition (correcting calcium cycling abnormalities) — are supported by an in-house drug discovery unit, Cardurion KK, based in Fujisawa, Japan, with 14 cardiovascular scientists. Cardurion is the first company to bring a PDE9 inhibitor into clinical development for chronic heart failure and the first to develop a CaMKII inhibitor for clinical evaluation. Its clinical advisory board includes James Udelson (Tufts), John McMurray (University of Glasgow), Scott Solomon (Harvard Medical School), and the late Eugene Braunwald (Harvard).

Cardurion has no commercial products and generates no product revenue. The company expects future revenue to come from pharmaceutical product sales upon regulatory approval, distributed through specialty pharmacies, hospital buying groups, and direct physician prescribing channels. The company is funded through venture capital, having raised approximately $260 million in a Series B led by Ascenta Capital in July 2024 (with Bain Capital having committed up to $300 million in 2021), bringing total committed capital above $560 million. Investors include Bain Capital, Ascenta Capital, NEA, GV, Fidelity, Millennium Management, Farallon, Invus, Blue Owl, Delos, and Digitalis Ventures. GTM motion is centered on multi-center clinical trial partnerships with leading academic cardiology institutions globally, with eventual commercial launch expected through specialty sales channels targeting cardiologists and heart failure specialists.

Short descriptiontext

Cardurion Pharmaceuticals is a clinical-stage cardiovascular biotechnology company developing first-in-class PDE9 inhibitors (CRD-750, CRD-740) and the first-ever CaMKII inhibitor (CRD-4730) for heart failure, CPVT, and atrial fibrillation. It serves patients with cardiovascular diseases through clinical development headquartered in Burlington, Massachusetts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular therapeutics, heart failure drugs, clinical-stage biotechnology, PDE9 inhibitors, calcium signaling modulators
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiovascular Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Cardurion is a clinical-stage biotechnology company with no current commercial products. Revenue will be generated through sales of approved pharmaceutical products targeting cardiovascular diseases, once regulatory approval is obtained for PDE9 inhibitors (CRD-750) and CaMKII inhibitors (CRD-4730). The company is in Phase 2 clinical trials for multiple drug candidates.

cardurion.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cardurion Pharmaceuticals is a clinical-stage biotechnology company developing novel therapeutics for cardiovascular diseases, with two lead programs: PDE9 inhibitors (CRD-750 and CRD-740) targeting chronic heart failure (HFrEF and HFpEF) and the first-ever CaMKII inhibitor (CRD-4730) in clinical development targeting CPVT, heart failure, and atrial fibrillation. The company also maintains a preclinical TRPC6 inhibitor candidate. Drug candidates are being advanced through Phase 2 clinical trials and will ultimately be commercialized for prescription use by cardiologists and healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CRD-740 achieved statistically significant median increases in plasma cGMP at four weeks in Phase 2a CARDINAL-HF trial in HFrEF patients
+2 more records
Product overview1 text field

Cardurion Pharmaceuticals is a clinical-stage biotechnology company developing a pipeline of novel cardiovascular therapeutics. The company's clinical-stage pipeline consists of two groundbreaking programs: CRD-750 and CRD-740 (PDE9 inhibitors targeting heart failure) and CRD-4730 (CaMKII inhibitor for cardiovascular diseases). The drug candidates target phosphodiesterase-9 (PDE9) and calcium/calmodulin-dependent protein kinase II (CaMKII) signaling pathways to treat conditions including HFrEF, HFpEF, and CPVT.

Product and service6 records
1CRD-750
CategoryDrug Candidate
Description

An orally-administered phosphodiesterase 9 (PDE9) inhibitor being evaluated in Phase 2 clinical trials (CYCLE-1-REF and CYCLE-2-PEF) for the treatment of both types of chronic heart failure (HFrEF and HFpEF). Being developed for cardiology specialists and the broader heart failure patient population.

2CRD-740
CategoryDrug Candidate
Description

A phosphodiesterase 9 (PDE9) inhibitor that completed a Phase 2a CARDINAL-HF trial in patients with heart failure with reduced ejection fraction (HFrEF), demonstrating statistically significant median increase in plasma cGMP at four weeks. Targeted at heart failure patients with reduced ejection fraction.

3CRD-4730
4PDE9 Inhibitor Program
CategoryDrug Program
Description

Clinical program targeting phosphodiesterase-9 inhibition to enhance the natriuretic peptide signaling pathway for treating heart failure. Cardurion is the first company to bring a PDE9 inhibitor into clinical development for chronic heart failure, addressing both HFrEF and HFpEF patients.

5CaMKII Inhibitor Program
CategoryDrug Program
Description

Clinical program targeting calcium/calmodulin-dependent protein kinase II (CaMKII) for treating rare and common cardiovascular diseases including CPVT, heart failure, and atrial fibrillation. Cardurion is the first company to successfully develop a CaMKII inhibitor and evaluate it in clinical studies.

6TRPC6 Inhibitor
CategoryDrug Candidate (Discovery)
Description

A preclinical drug candidate targeting TRPC6 for cardiopulmonary indications, currently in the discovery stage of the Cardurion research and development pipeline.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Tufts Medical Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-11
Description

Clinical partnership with Tufts Medical Center for CARDINAL-HF Phase 2a trial. James Udelson, MD, Chief of Cardiology at Tufts Medical Center, served as Principal Investigator and leads Cardurion's Clinical Advisory Board. Scott Solomon, MD from Harvard Medical School also involved in clinical trials.

cardurion.com
2Clinical Advisory Board Members
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cardurion has assembled a world-class Clinical Advisory Board including James Udelson, MD (Tufts Medical Center), John McMurray, MD (University of Glasgow), Scott Solomon, MD (Harvard Medical School), and the late Eugene Braunwald, MD (Harvard Medical School) who served as founding member from 2017-2026. These experts guide clinical development, trial design, and regulatory affairs.

cardurion.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage company developing targeted therapies for cardiovascular and musculoskeletal diseases, including cardiac sarcomere modulators. Comparable to Cardurion as a smaller, cardiovascular-focused clinical-stage biotech with novel mechanism programs in cardiac disease.

TypeBroad incumbent
Description

Global pharmaceutical company whose Entresto (sacubitril/valsartan) is a foundational heart failure therapy and standard-of-care comparator for any new HFrEF entrant including Cardurion's CRD-750. Represents the commercial benchmark and potential acquirer/partner for new CV mechanisms.

TypeDirect peer
Description

Clinical-stage cardiovascular biotechnology company developing gene therapies and small molecules for heart failure and genetic cardiomyopathies. Comparable to Cardurion as a venture-backed, U.S.-headquartered CV biotech advancing differentiated mechanisms through clinical trials with similar investor profiles.

TypeBroad incumbent
Description

Global pharmaceutical company with Farxiga (dapagliflozin), an SGLT2 inhibitor now foundational in heart failure treatment. Represents an additional standard-of-care comparator and potential strategic acquirer for differentiated HF programs like Cardurion's PDE9 and CaMKII pipeline.

TypeDirect peer
Description

Clinical-stage cardiovascular biotechnology company developing cardiac myosin modulators (e.g., omecamtiv mecarbil, aficamten) for heart failure and hypertrophic cardiomyopathy. Directly comparable to Cardurion as a CV-focused clinical-stage biotech pursuing novel mechanisms in heart failure with similar trial designs and target patient populations.

6Stealth BioTherapeutics
TypeEmerging player
Description

Clinical-stage biotechnology company developing mitochondria-targeted therapeutics for cardiovascular and metabolic diseases including heart failure with preserved ejection fraction. Overlaps with Cardurion in pursuing novel cardiovascular mechanisms for HFpEF.

TypeBroad incumbent
Description

Late-stage commercial biopharmaceutical company with cardiovascular programs including acoramidis for transthyretin amyloid cardiomyopathy. Comparable as a broader cardiovascular-focused biopharma with deep clinical pipeline across multiple cardiac indications.

TypeEmerging player
Description

Clinical-stage gene therapy company with cardiovascular programs including Danon disease (RP-A501) and BAG3-associated dilated cardiomyopathy. Comparable as a cardiovascular-focused rare disease biotech with similar venture backing and clinical-stage development model.

TypeEmerging player
Description

Clinical-stage biotechnology company developing AAV-based gene therapies for genetically defined cardiovascular diseases including Friedreich's ataxia cardiomyopathy and arrhythmogenic cardiomyopathy. Comparable to Cardurion in pursuing differentiated cardiovascular mechanisms with strong academic and scientific backing.

TypeBroad incumbent
Description

Global pharmaceutical company with established cardiovascular franchise including Verquvo (vericiguat) for heart failure with reduced ejection fraction. Direct comparator to Cardurion's PDE9 program as a recent CV mechanism launch and incumbent in the HF treatment paradigm.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cardurion Pharmaceuticals

Cardiovascular Therapeuticscardurion.com

Cardurion Pharmaceuticals is a clinical-stage cardiovascular biotechnology company developing first-in-class PDE9 inhibitors (CRD-750, CRD-740) and the first-ever CaMKII inhibitor (CRD-4730) for heart failure, CPVT, and atrial fibrillation. It serves patients with cardiovascular diseases through clinical development headquartered in Burlington, Massachusetts.

What Cardurion Pharmaceuticals does

Cardurion Pharmaceuticals is a clinical-stage cardiovascular biotechnology company founded in 2017 by physician-scientist Michael E. Mendelsohn, M.D. (former Senior Vice President and Global Head of Cardiovascular Research at Merck Research Laboratories) and headquartered in Burlington, Massachusetts. The company develops novel therapeutics targeting cardiovascular signaling pathways — specifically phosphodiesterase 9 (PDE9) and calcium/calmodulin-dependent protein kinase II (CaMKII) — both previously considered difficult or "undruggable." Its lead program, CRD-750 (a PDE9 inhibitor), is being evaluated in two global Phase 2 trials: CYCLE-1-REF in heart failure with reduced ejection fraction (HFrEF, ~560 patients) and CYCLE-2-PEF in heart failure with preserved ejection fraction (HFpEF, ~300 patients), with enrollment completed in August 2025. A related molecule, CRD-740, generated statistically significant plasma cGMP increases in the Phase 2a CARDINAL-HF trial in HFrEF patients. The CaMKII inhibitor program is anchored by CRD-4730 in a Phase 2 trial for catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare genetic arrhythmic disease with no approved therapies, and is being explored for broader applications in heart failure and atrial fibrillation.

The company's core technology platforms — PDE9 inhibition (preventing cGMP degradation to enhance natriuretic peptide signaling) and CaMKII inhibition (correcting calcium cycling abnormalities) — are supported by an in-house drug discovery unit, Cardurion KK, based in Fujisawa, Japan, with 14 cardiovascular scientists. Cardurion is the first company to bring a PDE9 inhibitor into clinical development for chronic heart failure and the first to develop a CaMKII inhibitor for clinical evaluation. Its clinical advisory board includes James Udelson (Tufts), John McMurray (University of Glasgow), Scott Solomon (Harvard Medical School), and the late Eugene Braunwald (Harvard).

Cardurion has no commercial products and generates no product revenue. The company expects future revenue to come from pharmaceutical product sales upon regulatory approval, distributed through specialty pharmacies, hospital buying groups, and direct physician prescribing channels. The company is funded through venture capital, having raised approximately $260 million in a Series B led by Ascenta Capital in July 2024 (with Bain Capital having committed up to $300 million in 2021), bringing total committed capital above $560 million. Investors include Bain Capital, Ascenta Capital, NEA, GV, Fidelity, Millennium Management, Farallon, Invus, Blue Owl, Delos, and Digitalis Ventures. GTM motion is centered on multi-center clinical trial partnerships with leading academic cardiology institutions globally, with eventual commercial launch expected through specialty sales channels targeting cardiologists and heart failure specialists.

Cardurion Pharmaceuticals firmographics

Firmographics
Name
Cardurion Pharmaceuticals
Legal name
Cardurion Pharmaceuticals, Inc.
Website
https://cardurion.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Cardurion Pharmaceuticals is a clinical-stage cardiovascular biotechnology company developing first-in-class PDE9 inhibitors (CRD-750, CRD-740) and the first-ever CaMKII inhibitor (CRD-4730) for heart failure, CPVT, and atrial fibrillation. It serves patients with cardiovascular diseases through clinical development headquartered in Burlington, Massachusetts.
Ownership category
akta.pro rank

Cardurion Pharmaceuticals industry classification

Industry
Product category
Cardiovascular Therapeutics
NAICS
Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • Cardiovascular therapeutics
  • Heart failure drugs
  • Clinical-stage biotechnology
  • PDE9 inhibitors
  • Calcium signaling modulators

Where Cardurion Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cardurion Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Revenue: Cardurion is a clinical-stage biotechnology company with no current commercial products. Revenue will be generated through sales of approved pharmaceutical products targeting cardiovascular diseases, once regulatory approval is obtained for PDE9 inhibitors (CRD-750) and CaMKII inhibitors (CRD-4730). The company is in Phase 2 clinical trials for multiple drug candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Cardurion Pharmaceuticals product offering

Product offering

Core offering

Cardurion Pharmaceuticals is a clinical-stage biotechnology company developing novel therapeutics for cardiovascular diseases, with two lead programs: PDE9 inhibitors (CRD-750 and CRD-740) targeting chronic heart failure (HFrEF and HFpEF) and the first-ever CaMKII inhibitor (CRD-4730) in clinical development targeting CPVT, heart failure, and atrial fibrillation. The company also maintains a preclinical TRPC6 inhibitor candidate. Drug candidates are being advanced through Phase 2 clinical trials and will ultimately be commercialized for prescription use by cardiologists and healthcare providers.

Product overview

Cardurion Pharmaceuticals is a clinical-stage biotechnology company developing a pipeline of novel cardiovascular therapeutics. The company's clinical-stage pipeline consists of two groundbreaking programs: CRD-750 and CRD-740 (PDE9 inhibitors targeting heart failure) and CRD-4730 (CaMKII inhibitor for cardiovascular diseases). The drug candidates target phosphodiesterase-9 (PDE9) and calcium/calmodulin-dependent protein kinase II (CaMKII) signaling pathways to treat conditions including HFrEF, HFpEF, and CPVT.

Differentiator

Problem solved

Functional benefit

Products and services

  • CRD-750 An orally-administered phosphodiesterase 9 (PDE9) inhibitor being evaluated in Phase 2 clinical trials (CYCLE-1-REF and CYCLE-2-PEF) for the treatment of both types of chronic heart failure (HFrEF and HFpEF). Being developed for cardiology specialists and the broader heart failure patient population.
  • CRD-740 A phosphodiesterase 9 (PDE9) inhibitor that completed a Phase 2a CARDINAL-HF trial in patients with heart failure with reduced ejection fraction (HFrEF), demonstrating statistically significant median increase in plasma cGMP at four weeks. Targeted at heart failure patients with reduced ejection fraction.
  • CRD-4730
  • PDE9 Inhibitor Program Clinical program targeting phosphodiesterase-9 inhibition to enhance the natriuretic peptide signaling pathway for treating heart failure. Cardurion is the first company to bring a PDE9 inhibitor into clinical development for chronic heart failure, addressing both HFrEF and HFpEF patients.
  • CaMKII Inhibitor Program Clinical program targeting calcium/calmodulin-dependent protein kinase II (CaMKII) for treating rare and common cardiovascular diseases including CPVT, heart failure, and atrial fibrillation. Cardurion is the first company to successfully develop a CaMKII inhibitor and evaluate it in clinical studies.
  • TRPC6 Inhibitor A preclinical drug candidate targeting TRPC6 for cardiopulmonary indications, currently in the discovery stage of the Cardurion research and development pipeline.

Quantifiable outcome

  • CRD-740 achieved statistically significant median increases in plasma cGMP at four weeks in Phase 2a CARDINAL-HF trial in HFrEF patients
  • +2 more outcomes

Companies that use Cardurion Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles3 records

Cardurion Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cardurion Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Tufts Medical CentercoreStrategic or Co-development Partner · 11 May 2024Clinical partnership with Tufts Medical Center for CARDINAL-HF Phase 2a trial. James Udelson, MD, Chief of Cardiology at Tufts Medical Center, served as Principal Investigator and leads Cardurion's Clinical Advisory Board. Scott Solomon, MD from Harvard Medical School also involved in clinical trials.
  • Clinical Advisory Board MemberscoreStrategic or Co-development PartnerCardurion has assembled a world-class Clinical Advisory Board including James Udelson, MD (Tufts Medical Center), John McMurray, MD (University of Glasgow), Scott Solomon, MD (Harvard Medical School), and the late Eugene Braunwald, MD (Harvard Medical School) who served as founding member from 2017-2026. These experts guide clinical development, trial design, and regulatory affairs.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Cardurion Pharmaceuticals competitors and assessment

Company assessment

Emerging players

  • Edgewise Therapeutics: Clinical-stage company developing targeted therapies for cardiovascular and musculoskeletal diseases, including cardiac sarcomere modulators. Comparable to Cardurion as a smaller, cardiovascular-focused clinical-stage biotech with novel mechanism programs in cardiac disease.
  • Stealth BioTherapeutics: Clinical-stage biotechnology company developing mitochondria-targeted therapeutics for cardiovascular and metabolic diseases including heart failure with preserved ejection fraction. Overlaps with Cardurion in pursuing novel cardiovascular mechanisms for HFpEF.
  • Rocket Pharmaceuticals: Clinical-stage gene therapy company with cardiovascular programs including Danon disease (RP-A501) and BAG3-associated dilated cardiomyopathy. Comparable as a cardiovascular-focused rare disease biotech with similar venture backing and clinical-stage development model.
  • Lexeo Therapeutics: Clinical-stage biotechnology company developing AAV-based gene therapies for genetically defined cardiovascular diseases including Friedreich's ataxia cardiomyopathy and arrhythmogenic cardiomyopathy. Comparable to Cardurion in pursuing differentiated cardiovascular mechanisms with strong academic and scientific backing.

Broad incumbents

  • Novartis: Global pharmaceutical company whose Entresto (sacubitril/valsartan) is a foundational heart failure therapy and standard-of-care comparator for any new HFrEF entrant including Cardurion's CRD-750. Represents the commercial benchmark and potential acquirer/partner for new CV mechanisms.
  • AstraZeneca: Global pharmaceutical company with Farxiga (dapagliflozin), an SGLT2 inhibitor now foundational in heart failure treatment. Represents an additional standard-of-care comparator and potential strategic acquirer for differentiated HF programs like Cardurion's PDE9 and CaMKII pipeline.
  • BridgeBio Pharma: Late-stage commercial biopharmaceutical company with cardiovascular programs including acoramidis for transthyretin amyloid cardiomyopathy. Comparable as a broader cardiovascular-focused biopharma with deep clinical pipeline across multiple cardiac indications.
  • Bayer: Global pharmaceutical company with established cardiovascular franchise including Verquvo (vericiguat) for heart failure with reduced ejection fraction. Direct comparator to Cardurion's PDE9 program as a recent CV mechanism launch and incumbent in the HF treatment paradigm.

Direct peers

  • Tenaya Therapeutics: Clinical-stage cardiovascular biotechnology company developing gene therapies and small molecules for heart failure and genetic cardiomyopathies. Comparable to Cardurion as a venture-backed, U.S.-headquartered CV biotech advancing differentiated mechanisms through clinical trials with similar investor profiles.
  • Cytokinetics: Clinical-stage cardiovascular biotechnology company developing cardiac myosin modulators (e.g., omecamtiv mecarbil, aficamten) for heart failure and hypertrophic cardiomyopathy. Directly comparable to Cardurion as a CV-focused clinical-stage biotech pursuing novel mechanisms in heart failure with similar trial designs and target patient populations.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Cardurion Pharmaceuticals social profiles

Digital presence

Cardurion Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cardurion Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

Cardurion Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cardurion Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cardurion Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardurion Pharmaceuticals

What does Cardurion Pharmaceuticals do?

Cardurion Pharmaceuticals is a clinical-stage biotechnology company developing novel therapeutics for cardiovascular diseases, with two lead programs: PDE9 inhibitors (CRD-750 and CRD-740) targeting chronic heart failure (HFrEF and HFpEF) and the first-ever CaMKII inhibitor (CRD-4730) in clinical development targeting CPVT, heart failure, and atrial fibrillation. The company also maintains a preclinical TRPC6 inhibitor candidate. Drug candidates are being advanced through Phase 2 clinical trials and will ultimately be commercialized for prescription use by cardiologists and healthcare providers.

Is Cardurion Pharmaceuticals a public or private company?

Cardurion Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cardurion Pharmaceuticals founded?

Cardurion Pharmaceuticals was founded in 2017. It employs 51 to 100 people.

Where is Cardurion Pharmaceuticals based?

Cardurion Pharmaceuticals is headquartered in Burlington, United States, in the North America region.

How does Cardurion Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Cardurion Pharmaceuticals's main competitors?

Emerging players on record are Edgewise Therapeutics, Stealth BioTherapeutics, Rocket Pharmaceuticals and Lexeo Therapeutics. Broad incumbents are Novartis, AstraZeneca, BridgeBio Pharma and Bayer. Direct peers are Tenaya Therapeutics and Cytokinetics.

Does Cardurion Pharmaceuticals have an API?

No public API is recorded for Cardurion Pharmaceuticals.

What industry is Cardurion Pharmaceuticals in?

Cardurion Pharmaceuticals's product category is Cardiovascular Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart FailureCardurion Pharmaceuticals will present Phase 2 trial results for tovinontrine (CRD-750), a PDE9 inhibitor, at the HFSA meeting in October 2026. The trials assess the drug in heart failure with reduced and preserved ejection fraction. The company is the first to bring a PDE9 inhibitor into clinical development for chronic heart failure.Clinical Trials ArenaCardurion concludes enrolment in Phase II trials for heart failure treatmentUS-based Cardurion Pharmaceuticals has completed patient enrolment in two global Phase II clinical trials, CYCLE-1-REF and CYCLE-2-PEF, for its oral PDE9 inhibitor CRD-750 targeting heart failure. The trials enrolled approximately 860 subjects across HFrEF and HFpEF subtypes to assess the therapy's efficacy against a placebo using NT-proBNP as the primary endpoint. This milestone follows the company's $260 million Series B funding secured last year to advance its cardiovascular drug pipeline.GlobeNewswireCardurion Pharmaceuticals Completes Enrollment in Phase 2 CYCLE Trials Evaluating CRD-750, a Novel PDE9 inhibitor, in Heart FailureCardurion Pharmaceuticals completed enrollment in two Phase 2 trials evaluating CRD-750, a PDE9 inhibitor, in heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). The trials enrolled about 560 HFrEF patients and 300 HFpEF patients, with the primary endpoint being NT-proBNP change. Results are expected at a future medical meeting.Business Wire BlogCardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business OfficerCardurion Pharmaceuticals appointed Charlotte Newman as its Chief Business Officer to lead corporate development, business development, and portfolio strategy. Newman brings over 25 years of experience from previous roles at Agios Pharmaceuticals and Biogen. This leadership addition aims to help Cardurion maximize opportunities for its growing portfolio of cardiovascular drug candidates.Business Wire BlogCardurion Pharmaceuticals Selected as an Endpoints 11 Most Promising Biotech CompanyCardurion Pharmaceuticals has been named one of the Endpoints 11 most promising private biotechnology companies of 2024 by the Endpoints News editorial team. The recognition highlights the company's progress with its two first-in-class clinical programs, CRD-750 and CRD-4730, which are currently undergoing Phase 2 trials for cardiovascular diseases.Business Wire BlogCardurion Pharmaceuticals Appoints Ron Renaud to Board of DirectorsCardurion Pharmaceuticals appointed Ron Renaud to its Board of Directors. Renaud brings over 25 years of biotech leadership, including CEO roles at Cerevel, Translate Bio, and Idenix. The company is advancing phase two trials for heart failure and CPVT.Clinical Trials ArenaCardurion closes $260m in Series B to develop cardiovascular pipelineCardurion Pharmaceuticals has closed a $260 million Series B financing round to advance its cardiovascular drug pipeline, specifically funding late-stage trials for CRD-750 and CRD-4730. The company intends to use the capital to expand indications for these candidates and acquire additional assets for treating heart disorders. Investors in the round included Bain Capital and Ascenta Capital.FinSMEsCardurion Pharmaceuticals Raises $260M Series B FinancingCardurion Pharmaceuticals raised $260M in Series B financing led by Ascenta Capital, with participation from NEA, GV, and others. The company will use the funds for later-stage trials of its PDE9 and CaMKII inhibitors, including a Phase 2 trial in 640 heart failure patients. It also plans to expand cardiovascular indications and acquire additional assets.ContractpharmaCardurion Raises $260M Series B FinancingCardurion Pharmaceuticals raised $260 million in Series B financing led by Ascenta Capital, with participation from NEA, GV, Fidelity, and others. The funds will support later-stage trials for its PDE9 and CaMKII inhibitors, including a Phase 2 trial in 640 heart failure patients. The company will also expand cardiovascular indications and acquire additional assets.VC News DailyCardurion Pharmaceuticals Inks $260M Series BCardurion Pharmaceuticals announced the closing of a $260 million Series B financing round led by Ascenta Capital. The investment, which includes participation from NEA, GV, Fidelity Management & Research Company, and other institutional investors, will support the company's clinical-stage biotechnology programs for cardiovascular diseases.